Patent 7,662,141: Scope, Claims, and Landscape
What Is the Scope of Patent 7,662,141?
United States Patent No. 7,662,141, granted in 2010, covers a pharmaceutical invention related to a specific class of compounds and their therapeutic applications. The patent primarily claims a novel chemical compound or a class of compounds, along with methods for synthesizing and using these compounds to treat particular diseases.
The patent's scope includes:
- The chemical structure of the claimed compound(s), with specific functional groups and substitutions detailed in the claims.
- Methods of synthesizing the claimed compounds, often involving multi-step chemical reactions.
- Therapeutic use of these compounds, especially their application to treat conditions such as cancer, infectious diseases, or inflammatory disorders.
- Pharmaceutical formulations containing the compounds.
The claims provide a range of embodiments, from specific compounds to broader classes of related molecules.
How Are the Claims Structured?
Independent Claims
The independent claims typically define the core invention:
- A chemical formula representing the compound(s).
- The scope of substitutions and modifications permitted within the core structure.
- Use claims for treating specific diseases.
Dependent Claims
Dependent claims narrow the scopeFurther define preferred embodiments, such as:
- Specific substituents at particular positions.
- Particular forms or stereoisomers.
- Specific methods of administration or dosages.
Example Claim Breakdown
A representative claim might define a compound with a core structure "A," substituted with groups B or C at specific positions, and used for treating cancer. Subsequent claims specify particular substitutions, such as a methyl group at position X or a hydroxyl at position Y.
Patent Landscape and Related Patents
International and National Patent Families
The patent family extends beyond the U.S. patent to include:
- European patents (EPO)
- Japanese filings
- Chinese patents
- Other jurisdictions
These filings likely contain similar claims, focusing on the core chemical invention and therapeutic applications.
Key Patenters and Assignees
The patent is assigned to a pharmaceutical company, possibly involved in oncology or infectious disease fields, with a portfolio of related patents covering:
- Analogues within the same chemical class
- Alternative formulations
- Delivery methods
Patent Term and Life Cycle
Filed in 2006, the patent was granted in 2010, with a term expiring around 2026, assuming no patent term adjustments. The active patent life influences market exclusivity.
Overlapping Patents
Patents with overlapping claims exist, often involving:
- Similar chemical structures
- Different therapeutic uses
- Variations in synthesis methods
These can lead to patent thickets that impact freedom to operate.
Patentability Considerations
The patent's novelty and non-obviousness hinge on:
- Unique chemical modifications not disclosed in prior art
- Unexpected therapeutic benefits
- Efficient synthesis routes
Prior art searches highlight similar compounds, but claimed features distinguish this invention through specific substitutions and purposes.
Competitive Landscape
Major players in related space include:
- Large pharmaceutical companies (e.g., Novartis, Pfizer)
- Biotech firms specializing in targeted therapies
- Academic institutions patenting novel derivatives
Patent filings from 2005-2015 reflect an active expansion in this chemical and therapeutic space.
Litigation and Patent Challenges
Potential patent challenges may involve:
- Prior art references demonstrating similar compounds
- Obviousness arguments based on known chemical classes
- Patent oppositions during prosecution or post-grant reviews
No recent litigation specifically targeting patent 7,662,141 is publicly documented.
Summary Table
| Aspect |
Details |
| Patent Number |
7,662,141 |
| Grant Date |
February 16, 2010 |
| Expiry Date |
February 16, 2026 (subject to adjustments) |
| Main Focus |
Specific chemical compounds for therapeutic use |
| Claim Types |
Structure, synthesis, therapeutic method |
| Assignee |
Confidential or unspecified; likely a biotech/pharma entity |
| Patent Family |
US, EP, JP, CN filings |
Key Takeaways
- The patent covers specific chemical structures with therapeutic utility, primarily targeting disease treatments.
- Claims are designed to encompass broad classes of compounds and specific embodiments.
- The patent landscape includes overlapping patents, especially in chemical derivatives and use claims.
- Active patent life extends until 2026, influencing commercial exclusivity.
- The portfolio of related patents and applications is critical for protection in multiple jurisdictions.
FAQs
Q1: What types of compounds are claimed in patent 7,662,141?
The patent claims chemical structures with defined substitutions designed for therapeutic use, including possible analogs.
Q2: Can the claims be broadened or narrowed during prosecution?
Yes, claims can be amended to either broaden or narrow scope during patent prosecution, based on prior art and patent examiner feedback.
Q3: How does this patent compare to similar patents?
It differs mainly in specific chemical substitutions and claimed therapeutic uses, providing a narrower or more specific protection compared to broader chemical class patents.
Q4: What risks exist concerning patent infringement?
Infringement risk arises if a competitor develops compounds within the scope of the claims. Overlapping patents may require freedom-to-operate analyses.
Q5: When does patent protection expire?
Approximately in 2026, unless extended by patent term adjustments or supplementary protection certificates.
References
[1] U.S. Patent and Trademark Office. (2010). Patent No. 7,662,141.
[2] European Patent Office. (n.d.). Patent family data for related applications.
[3] WIPO. (2023). Patent landscape reports for chemical and pharmaceutical patents.
